BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success

12 hours ago 1

Maham Fatima

Tue, March 3, 2026 astatine 1:21 AM CST 2 min read

BridgeBio Pharma Inc. (NASDAQ:BBIO) is 1 of the stocks with explosive maturation potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge successful full gross to $502.1 million. This was driven mostly by the commercialized occurrence of its flagship product, Attruby. In Q4 alone, Attruby generated $146 cardinal successful nett merchandise revenue, reflecting a 35% summation implicit Q3. This maturation was supported by 7,804 caller diligent starts and precocious levels of diligent persistence.

The institution achieved important objective milestones with 3 affirmative Phase 3 readouts successful precocious 2025: Encaleret for ADH1, BBP-418 for LGMD2I, and Infigratinib for achondroplasia. These successes presumption BridgeBio to modulation from a single-product institution to 1 with perchance six approved medicines by the extremity of its archetypal decade. NDAs for some Encaleret and BBP-418 are expected successful H1 2026, with US launches targeted for precocious 2026 oregon aboriginal 2027.

Charles River Laboratories International, Inc. (CRL) Faces Biotech R&D Spending Headwinds

Management highlighted that Attruby’s near-complete stabilization of transthyretin serves arsenic a cardinal objective differentiator that should support its marketplace stock adjacent arsenic imaginable generic competitors for tafamidis emerge. While the nett nonaccomplishment for the twelvemonth widened to $724.9 million, BridgeBio Pharma Inc. (NASDAQ:BBIO) expects currency pain to stabilize and yet alteration arsenic Attruby’s margins grow and caller products participate the market.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is simply a biopharmaceutical institution that discovers, develops, and delivers medicines for patients with familial diseases.

While we admit the imaginable of BBIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Stocks for Beginners with Little Money successful 2026.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article